FDA expands Welireg label for additional kidney cancer indication
FDA action · Zacks Investment Research · 2026-09-28. Number 2 in the UrologyWatch Top 5 for September 29, 2026.
Merck's belzutifan (Welireg) received an expanded FDA label covering a new indication in kidney cancer.
Why it matters: Broader labeling may extend access to belzutifan for additional renal cell carcinoma patient populations.
Source: Zacks Investment Research
Loading today's edition…